Cardiology Today's Intervention Current Issue
The following articles appeared in the print edition of Cardiology Today's Intervention.
Table of Contents
- Controversy in the Cath Lab
-
- A Conversation with Dean J. Kereiakes, MD
- AngioDynamics to Purchase Navilyst Medical for $372 million
- BridgePoint Medical, Covidien Reach Agreement on Peripheral Vascular Devices
- C.R. Bard Acquires PTA Balloon Manufacturer
- Sanofi-Aventis, Bristol-Myers Squibb Collect Damages in Clopidogrel Litigation
- US Interventional Cardiology Market Forecast: Decline Expected Through 2016
- The Szabo Technique in a Patient with Ostial RCA In-Stent Restenosis
- Assessment of Prasugrel in Randomized Trials Confirmed in 'Real World'
-
- Behavioral Intervention Found Critical in Patients Sustaining Physical Activity After PCI
- DES May Be Preferable to BMS in Oldest Patients
- EVEREST II Substudy Affirms Feasibility, Efficacy of Percutaneous Mitral Leaflet Repair
- New-Generation DES Outperformed Old in Swedish Registry
- Processing FAME II: Enrollment Halted After Positive Results Observed for OMT Plus FFR-guided PCI
- PROTECT Trial Highlights Improvements in Carotid Artery Stenting
- Two Programs Launched to Examine Renal Denervation System
- Optimizing Coronary Revascularization with Near-Infrared Spectroscopy Joshua M. Stolker, MD
-
- Deconstructing Longitudinal Stent Deformation
- Drug-Coated Balloons and Stents for Endovascular Treatment of PAD Subhash Banerjee, MD
- AAA Stent Graft System Obtains CE Mark
- ACS Indication Sought for Rivaroxaban
- CMS proposes coverage plan for TAVR
- FDA, Device Industry Strike Deal on Review Process Fees
- FDA-Approved DES for CAD is First to Feature Diabetes Indication
- Concerns and Challenges Selecting Patients for MitraClip or TAVR Peter C. Block, MD
-